# Guangxi Zhuang Autonomous Region Health and Family Planning

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/guangxi-zhuang-autonomous-region-health-and-family-planning/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 64 |
| Citations | 17,435 |
| City | Nanning |
| Country | CN |
| Description | Guangxi Zhuang Autonomous Region Health and Family Planning is a research organisation in Nanning, CN. OpenAlex records 1,524 works and 17,435 citations for it. 996 researchers list it as their most recent affiliation. |
| Homepage | http://www.gxhfpc.gov.cn/ |
| OpenAlex ID | https://openalex.org/I4210112430 |
| Region | Guangxi |
| Researchers | 996 |
| ROR ID | https://ror.org/022z3g211 |
| Type | government |
| Works | 1,524 |

## University papers

Showing 12 of 16.

- [Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study](https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial](https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for-the-treatment/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)](https://scholariq.org/papers/efficacy-safety-and-correlative-biomarkers-of-toripalimab-in-previously-treated/)
- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)
- [Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/tucidinostat-plus-exemestane-for-postmenopausal-patients-with-advanced-hormone/)

## University top topics

Showing 8 of 24.

- [Heavy metals in environment](https://scholariq.org/topics/heavy-metals-in-environment/)
- [Remote Sensing in Agriculture](https://scholariq.org/topics/remote-sensing-in-agriculture/)
- [Reproductive Biology and Fertility](https://scholariq.org/topics/reproductive-biology-and-fertility/)
- [Insect-Plant Interactions and Control](https://scholariq.org/topics/insect-plant-interactions-and-control/)
- [Soil Carbon and Nitrogen Dynamics](https://scholariq.org/topics/soil-carbon-and-nitrogen-dynamics/)
- [IoT and Edge/Fog Computing](https://scholariq.org/topics/iot-and-edge-fog-computing/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)
- [Privacy-Preserving Technologies in Data](https://scholariq.org/topics/privacy-preserving-technologies-in-data/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.